1. Home
  2. CYTK
  3. CYTK News

Latest Cytokinetics Incorporated (CYTK) News on December 22, 2024

Why Cytokinetics Stock Was a Nearly 5% Winner Today
CYTK

Motley Fool

2 days ago

Why Cytokinetics Stock Was a Nearly 5% Winner Today

CYTK

MT Newswires

2 days ago

Cytokinetics Says Sanofi Acquiring Rights for Aficamten in Greater China

Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
CYTK

GlobeNewswire

2 days ago

Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

Calculating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK)
CYTK

Simply Wall St.

3 days ago

Calculating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK)

CYTK

MT Newswires

4 days ago

RBC Raises Price Target on Cytokinetics to $82 From $80, Keeps Outperform, Speculative Risk

CYTK

Argus Research

4 days ago

CYTK: Lowering target price to $50.00

CYTK

Argus Research

11 days ago

CYTK: Rating increased to a HOLD

CYTK

MT Newswires

12 days ago

Cytokinetics Insider Sold Shares Worth $369,639, According to a Recent SEC Filing

Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?
CYTK

Zacks

16 days ago

Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?

Cytokinetics Initiates Confirmatory Study on Heart Failure Drug
CYTK

Zacks

18 days ago

Cytokinetics Initiates Confirmatory Study on Heart Failure Drug

CYTK

Argus Research

18 days ago

CYTK: Lowering target price to $41.00

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CYTK

GlobeNewswire

19 days ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CYTK

MT Newswires

19 days ago

Sector Update: Health Care Stocks Mixed Late Afternoon

FDA Accepts Cytokinetics' Application for Cardiovascular Drug
CYTK

Zacks

19 days ago

FDA Accepts Cytokinetics' Application for Cardiovascular Drug

CYTK

MT Newswires

19 days ago

Cytokinetics Begins Phase 3 Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure

Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction
CYTK

GlobeNewswire

19 days ago

Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction

Cytokinetics to Participate in December Investor Conferences
CYTK

GlobeNewswire

20 days ago

Cytokinetics to Participate in December Investor Conferences

CYTK

MT Newswires

20 days ago

Cytokinetics Says US FDA Accepts New Drug Application for Aficamten to Treat Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
CYTK

GlobeNewswire

20 days ago

Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date
CYTK

BioPharma Dive

20 days ago

Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date

Cytokinetics price target raised to $103 from $99 at Mizuho
CYTK

TipRanks

a month ago

Cytokinetics price target raised to $103 from $99 at Mizuho

Why Is Cytokinetics, Incorporated (CYTK) Among the Worst Performing Biotech Stocks in 2024?
CYTK

Insider Monkey

a month ago

Why Is Cytokinetics, Incorporated (CYTK) Among the Worst Performing Biotech Stocks in 2024?

Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan
CYTK

Zacks

a month ago

Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan

Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer
CYTK

BioPharma Dive

a month ago

Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer

CYTK

MT Newswires

a month ago

Cytokinetics, Bayer Partner to Develop, Commercialize Potential Cardiomyopathy Treatment in Japan

Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan
CYTK

GuruFocus.com

a month ago

Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan

Cytokinetics and Bayer Partner to Expand Aficamten's Reach in Japan
CYTK

GuruFocus.com

a month ago

Cytokinetics and Bayer Partner to Expand Aficamten's Reach in Japan

Bayer acquires rights to Cytokinetics' heart drug in Japan
CYTK

Reuters

a month ago

Bayer acquires rights to Cytokinetics' heart drug in Japan

Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan
CYTK

GlobeNewswire

a month ago

Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan

Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024
CYTK

GlobeNewswire

a month ago

Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024

Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024
CYTK

GlobeNewswire

a month ago

Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024

CYTK

MT Newswires

a month ago

Cytokinetics Insider Sold Shares Worth $370,880, According to a Recent SEC Filing

CYTK

Argus Research

a month ago

CYTK: Raising target price to $45.00

Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference
CYTK

GlobeNewswire

a month ago

Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference

CYTK

MT Newswires

a month ago

Cytokinetics Doses First Participants in Study of Potential Muscular Dystrophy Treatment

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089
CYTK

GlobeNewswire

a month ago

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089

CYTK

MT Newswires

a month ago

RBC Starts Cytokinetics With Outperform Rating, $80 Price Target

Cytokinetics Third Quarter 2024 Earnings: Misses Expectations
CYTK

Simply Wall St.

a month ago

Cytokinetics Third Quarter 2024 Earnings: Misses Expectations

CYTK

MT Newswires

a month ago

Cytokinetics Q3 Loss Widens, Revenue Rises

Cytokinetics Inc (CYTK) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
CYTK

GuruFocus.com

a month ago

Cytokinetics Inc (CYTK) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates
CYTK

Zacks

2 months ago

Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates

CYTK

Associated Press Finance

2 months ago

Cytokinetics: Q3 Earnings Snapshot

Cytokinetics Reports Third Quarter 2024 Financial Results
CYTK

GlobeNewswire

2 months ago

Cytokinetics Reports Third Quarter 2024 Financial Results

CYTK

Argus Research

2 months ago

CYTK: Raising target price to $42.00

Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024
CYTK

GlobeNewswire

2 months ago

Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024

Earnings To Watch: Cytokinetics Inc (CYTK) Reports Q3 2024 Result
CYTK

GuruFocus.com

2 months ago

Earnings To Watch: Cytokinetics Inc (CYTK) Reports Q3 2024 Result

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CYTK

GlobeNewswire

2 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics to Announce Third Quarter Results on November 6, 2024
CYTK

GlobeNewswire

2 months ago

Cytokinetics to Announce Third Quarter Results on November 6, 2024

Is Cytokinetics Inc. (CYTK) the Most Promising Biotech Stock According to Hedge Funds?
CYTK

Insider Monkey

2 months ago

Is Cytokinetics Inc. (CYTK) the Most Promising Biotech Stock According to Hedge Funds?

Cytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst Day
CYTK

GlobeNewswire

2 months ago

Cytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst Day

CYTK

MT Newswires

2 months ago

Cytokinetics Insider Sold Shares Worth $278,050, According to a Recent SEC Filing

Cytokinetics Inc (CYTK) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
CYTK

GuruFocus.com

2 months ago

Cytokinetics Inc (CYTK) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

CYTK

Argus Research

2 months ago

CYTK: Rating decreased to a SELL

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CYTK

GlobeNewswire

3 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics to Host Investor & Analyst Day on October 16, 2024
CYTK

GlobeNewswire

3 months ago

Cytokinetics to Host Investor & Analyst Day on October 16, 2024

Is Cytokinetics Inc. (CYTK) Positioned for Success with Its Innovative Muscle Modulators?
CYTK

Insider Monkey

3 months ago

Is Cytokinetics Inc. (CYTK) Positioned for Success with Its Innovative Muscle Modulators?

Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting
CYTK

GlobeNewswire

3 months ago

Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting

CYTK

MT Newswires

3 months ago

Cytokinetics New Analysis of Heart Medication Study Shows Beneficial Changes

Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions
CYTK

GlobeNewswire

3 months ago

Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions

Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program
CYTK

GlobeNewswire

3 months ago

Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program

How Edgewise, Up 55%, Is Hoping To Edge Out Bristol, Cytokinetics In Heart Disease
CYTK

Investor's Business Daily

3 months ago

How Edgewise, Up 55%, Is Hoping To Edge Out Bristol, Cytokinetics In Heart Disease

Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting
CYTK

GlobeNewswire

3 months ago

Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting

CYTK

MT Newswires

3 months ago

Cytokinetics Insider Sold Shares Worth $414,401, According to a Recent SEC Filing

Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study
CYTK

Benzinga

3 months ago

Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study

CYTK

MT Newswires

3 months ago

Cytokinetics Reports Phase 1 Study of CK-4021586 Meets Targets, Plans Mid-Stage Trial in Q4

Cytokinetics Announces Data From Phase 1 Study of CK-4021586
CYTK

GlobeNewswire

3 months ago

Cytokinetics Announces Data From Phase 1 Study of CK-4021586

Is Cytokinetics, Incorporated (CYTK) a Good Biotech Stock According to Hedge Funds?
CYTK

Insider Monkey

3 months ago

Is Cytokinetics, Incorporated (CYTK) a Good Biotech Stock According to Hedge Funds?

Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting
CYTK

GlobeNewswire

4 months ago

Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CYTK

GlobeNewswire

4 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Insider Sale: EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)
CYTK

GuruFocus.com

4 months ago

Insider Sale: EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)

Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024
CYTK

GlobeNewswire

4 months ago

Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024

Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024
CYTK

GlobeNewswire

4 months ago

Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024

Cytokinetics to Participate in September Investor Conferences
CYTK

GlobeNewswire

4 months ago

Cytokinetics to Participate in September Investor Conferences

CYTK

Argus Research

4 months ago

CYTK: What does Argus have to say about CYTK?

Insider Sale: EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)
CYTK

GuruFocus.com

4 months ago

Insider Sale: EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)

CYTK

MT Newswires

4 months ago

Cytokinetics Insider Sold Shares Worth $410,638, According to a Recent SEC Filing

CYTK

Argus Research

4 months ago

CYTK: What does Argus have to say about CYTK?

CYTK

MT Newswires

4 months ago

Goldman Sachs Downgrades Cytokinetics to Neutral From Buy, Adjusts Price Target to $60 From $85

CYTK

MT Newswires

4 months ago

Cytokinetics Insider Sold Shares Worth $276,000, According to a Recent SEC Filing

CYTK

MT Newswires

4 months ago

Cytokinetics Insider Sold Shares Worth $634,455, According to a Recent SEC Filing

Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in Focus
CYTK

Zacks

4 months ago

Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in Focus

Cytokinetics (CYTK) Reports Q2 Loss, Lags Revenue Estimates
CYTK

Zacks

4 months ago

Cytokinetics (CYTK) Reports Q2 Loss, Lags Revenue Estimates

CYTK

MT Newswires

4 months ago

Cytokinetics Q2 Loss Narrows, Revenue Declines

CYTK

Associated Press Finance

4 months ago

Cytokinetics: Q2 Earnings Snapshot

Cytokinetics Reports Second Quarter 2024 Financial Results
CYTK

GlobeNewswire

4 months ago

Cytokinetics Reports Second Quarter 2024 Financial Results

EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)
CYTK

GuruFocus.com

4 months ago

EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
CYTK

GlobeNewswire

5 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

CYTK

MT Newswires

5 months ago

Cytokinetics Insider Sold Shares Worth $684,135, According to a Recent SEC Filing

Investors in Cytokinetics (NASDAQ:CYTK) have seen incredible returns of 381% over the past five years
CYTK

Simply Wall St.

5 months ago

Investors in Cytokinetics (NASDAQ:CYTK) have seen incredible returns of 381% over the past five years

Cytokinetics Announces Call for Proposals for Corporate Giving Program
CYTK

GlobeNewswire

5 months ago

Cytokinetics Announces Call for Proposals for Corporate Giving Program

Cytokinetics to Announce Second Quarter Results on August 8, 2024
CYTK

GlobeNewswire

5 months ago

Cytokinetics to Announce Second Quarter Results on August 8, 2024

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?
CYTK

Zacks

5 months ago

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?

CYTK

Argus Research

5 months ago

CYTK: Raising target price to $46.00

Insider Sale: EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)
CYTK

GuruFocus.com

5 months ago

Insider Sale: EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)

CYTK

MT Newswires

5 months ago

Cytokinetics Insider Sold Shares Worth $416,246, According to a Recent SEC Filing

CYTK

Argus Research

5 months ago

CYTK: Raising target price to $45.00

Cytokinetics Announces Seven Upcoming Presentations at the European Society of Cardiology Congress 2024
CYTK

GlobeNewswire

5 months ago

Cytokinetics Announces Seven Upcoming Presentations at the European Society of Cardiology Congress 2024

Cytokinetics' Wild Ride: CEO Defends Deal That Rattled Wall Street
CYTK

Investor's Business Daily

5 months ago

Cytokinetics' Wild Ride: CEO Defends Deal That Rattled Wall Street

Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal?
CYTK

Investor's Business Daily

5 months ago

Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal?

Insider Sale: EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)
CYTK

GuruFocus.com

5 months ago

Insider Sale: EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)

Share on Social Networks: